Extravan
Generic name: travoprost and timolol
Treatment for: Glaucoma
Alcon Receives Approvable Letter for Extravan
FORT WORTH, Texas--September 17, 2004 - Alcon, Inc. (NYSE:ACL) today announced that the U.S. Food and Drug Administration (FDA) has issued an approvable letter for Extravan ophthalmic solution for the treatment of glaucoma. Extravan solution is a fixed combination of travoprost 0.004 percent and timolol 0.5 percent.
"We will be meeting with the FDA as soon as possible to clarify what additional steps may be required to gain final approval to market Extravan," said Dr. Scott Krueger, Alcon's Vice President of Regulatory Affairs.
Alcon is the world's leading eye care company and has been dedicated to the ophthalmic industry for more 57 years. Alcon develops, manufactures and markets pharmaceuticals, surgical equipment and devices, contact lens solutions and other vision care products that treat diseases, disorders and other conditions of the eye.
Posted: September 2004
Related articles
- Alcon Files NDA for Combination Drug to Treat Glaucoma; Releases PreliminaryClinical Data at Major Ophthalmology Meeting - January 28, 2004
Extravan (travoprost and timolol ) FDA Approval History
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.